Stereotactic radiosurgery (SRS) is a non-invasive treatment that delivers highly focused beams of radiation to a precise target in the brain or spine, destroying abnormal tissue without a single incision. Despite the name, there’s no scalpel or cutting involved. The “surgery” refers to the precision: modern systems can target tissue with accuracy down to fractions of a millimeter, sparing the surrounding healthy brain.
How It Works
SRS concentrates a high dose of radiation, typically 15 to 25 Gy delivered in one or two sessions, onto a small, well-defined target. Each individual beam passing through the skull is too weak to damage healthy tissue. But where dozens or even hundreds of beams converge at the target, the combined dose is powerful enough to damage cells beyond repair.
The biological effect is more complex than simply breaking DNA. While radiation does cause DNA damage that prevents tumor cells from dividing, researchers have found that DNA damage alone can’t fully explain why SRS is so effective. At the doses used, SRS also appears to damage the blood vessels feeding tumors, cutting off their supply and triggering additional cell death. This combination of direct cell damage and vascular disruption is what makes a single, concentrated treatment session potent enough to replace what would otherwise require weeks of conventional radiation or open surgery.
What Conditions SRS Treats
SRS was originally developed to treat functional brain disorders. The very first procedure, performed decades ago, targeted trigeminal neuralgia, a condition causing severe facial pain. Today the list of treatable conditions is much broader:
- Brain metastases: Cancers that have spread to the brain from elsewhere in the body. This is one of the most common uses.
- Benign brain tumors: Including meningiomas, vestibular schwannomas (acoustic neuromas), pituitary adenomas, and hemangioblastomas.
- Vascular malformations: Arteriovenous malformations (AVMs) and dural arteriovenous fistulas, where abnormal tangles of blood vessels pose a risk of bleeding.
- Functional disorders: Trigeminal neuralgia, certain types of epilepsy, and movement disorders in patients who aren’t candidates for open surgery or deep brain stimulation.
- Spinal and paraspinal lesions: Most commonly vertebral metastases causing cancer-related pain, as well as primary spinal tumors.
For trigeminal neuralgia specifically, 50% to 80% of patients achieve complete pain relief after SRS, though some require a repeat treatment. For epilepsy related to AVMs, seizure remission rates average around 70%.
Tumor Size Limits
Traditionally, tumors larger than 3 centimeters in diameter (or about 14 cubic centimeters in volume) were considered poor candidates for SRS. Larger targets make it harder to deliver a high enough dose without increasing radiation exposure to surrounding healthy tissue. This 3-centimeter threshold is still a common guideline, though recent studies have shown that outcomes for larger benign tumors can be comparable to those seen with smaller ones. Your treatment team will weigh tumor size, location, and type when deciding whether SRS is appropriate.
The Three Main Systems
Three platforms dominate SRS today, and while they differ in how they generate and aim radiation, all achieve the same goal of precise, focused treatment.
The Gamma Knife uses roughly 200 small cobalt-60 sources arranged in a helmet-like device, all aimed at a single point. It’s designed exclusively for intracranial targets. The latest model, the Gamma Knife Icon, added onboard imaging that allows the use of a non-invasive mask instead of a rigid head frame, opening up multi-session treatments.
Linear accelerator (LINAC) systems, such as the Varian TrueBeam, are standard radiation machines adapted for radiosurgery. They use a single beam that rotates around the patient, shaping the radiation field with tiny movable leaves. Because they’re versatile, these machines treat both brain and body targets.
The CyberKnife mounts a compact linear accelerator on a robotic arm, allowing it to aim from hundreds of different angles. It tracks the target in real time and adjusts for small movements, which makes it useful for both cranial and spinal treatments. Its latest versions include multileaf collimators for faster, more refined beam shaping.
What Happens During Treatment
The process starts with immobilization. For frame-based treatment, a lightweight metal frame is attached to the skull with four pins under local anesthesia. This locks the head in place with extreme precision but can be uncomfortable, and pin placement occasionally carries minor risks of bleeding or infection. For frameless treatment, a custom-fitted thermoplastic mask is molded to the patient’s face. The mask approach skips the pins and sedation entirely and makes it possible to split treatment across multiple sessions if needed.
Next comes imaging. An MRI and sometimes a CT scan map the target in three dimensions. These scans are fused together so the treatment team can outline the tumor or lesion and plan exactly where each beam will land. With the latest systems, onboard cone-beam CT scans taken just before treatment confirm the target’s position to sub-millimeter accuracy.
The treatment itself is painless. You lie still while the machine delivers radiation. The entire procedure, including setup, imaging, planning, and delivery, can take up to four hours depending on the size and shape of the target. Some sessions are shorter. You’re awake throughout, and there’s no sensation when the beams are active.
Precision and Accuracy
What sets SRS apart from conventional radiation therapy is its targeting precision. Modern Gamma Knife systems achieve a physical accuracy approaching 0.30 millimeters, roughly the thickness of three sheets of paper. In clinical practice, one technique demonstrated an average targeting accuracy of 0.34 millimeters, three to four times more precise than previously reported methods. This level of accuracy is what allows such high radiation doses to be delivered safely: the dose drops off sharply at the edge of the target, protecting nearby healthy brain tissue.
How It Compares to Open Surgery
For small to medium tumors, SRS can match or outperform traditional surgery with far less disruption. A study comparing SRS to microsurgical removal for acoustic neuromas smaller than 3 centimeters found that radiosurgery was significantly better at preserving normal facial nerve function and hearing. Patients returned to independent functioning sooner, spent less time in the hospital, and had lower overall treatment costs. Treatment-related complications were also significantly lower in the radiosurgery group.
That said, SRS doesn’t physically remove the tumor. It damages cells so they stop growing, and the tumor may shrink over months or years, but residual tissue often remains visible on scans. Open surgery is still preferred when a tumor needs to be removed immediately due to its size, location, or pressure on critical structures.
Effectiveness
For brain metastases, local tumor control rates are consistently high. In one single-center study of 108 patients treated for one to five brain metastases, the overall local control rate was about 90%, and both the one-year and two-year control rates held at roughly 91%. “Local control” means the treated tumor did not regrow at the same site. These figures make SRS a reliable option for patients with a limited number of brain metastases, particularly those who want to avoid the cognitive side effects of whole-brain radiation.
Recovery and Side Effects
Recovery is one of the biggest advantages. Most people return to their usual activities within a day or two. There’s no surgical wound, no general anesthesia, and no extended hospital stay. Mild fatigue, headache, or nausea in the first day or two is common but typically short-lived.
The most significant long-term risk is radiation necrosis, where treated brain tissue dies and swells months after the procedure. This occurs in roughly 5% to 25% of SRS patients, usually appearing 6 to 18 months after treatment. It can show up as an incidental finding on a follow-up scan with no symptoms at all, or it can cause headaches, seizures, or neurological changes. Mild cases may need only monitoring, while more severe cases require medical management. The wide range in incidence reflects differences in tumor size, dose, and location.
Follow-up imaging is a standard part of post-SRS care. Regular MRI scans track whether the treated area is stable, shrinking, or showing signs of necrosis or regrowth. Because the full effect of SRS unfolds over weeks to months, patience is built into the process.